# Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC

> **NCT00859339** · PHASE2 · TERMINATED · sponsor: **Noah Hahn, M.D.** · enrollment: 9 (actual)

## Conditions studied

- Transitional Cell Carcinoma of the Bladder

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Sunitinib Malate
- **PROCEDURE:** Radical Cystectomy

## Key facts

- **NCT ID:** NCT00859339
- **Lead sponsor:** Noah Hahn, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Patient Toxicities
- **Last updated:** 2016-04-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00859339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00859339, "Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00859339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*